Alexandra Goll - Net Worth and Insider Trading

Alexandra Goll Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Alexandra Goll owns 5 companies in total, including Protara Therapeutics Inc (TARA) , Enanta Pharmaceuticals Inc (ENTA) , and Concert Pharmaceuticals Inc (CNCE) among others .

Click here to see the complete history of Alexandra Goll’s form 4 insider trades.

Insider Ownership Summary of Alexandra Goll

Ticker	Comapny	Transaction Date	Type of Owner
TARA	Protara Therapeutics Inc	2014-10-21	10 percent owner
ENTA	Enanta Pharmaceuticals Inc	2013-03-20	10 percent owner
CNCE	Concert Pharmaceuticals Inc	2014-02-12	10 percent owner
		2014-02-06	10 percent owner
		2013-06-18	10 percent owner

Alexandra Goll Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Alexandra Goll Ownership Network

Ownership Network List of Alexandra Goll

No Data

Ownership Network Relation of Alexandra Goll

Alexandra Goll Owned Company Details

What does Protara Therapeutics Inc do?

Who are the key executives at Protara Therapeutics Inc?

Alexandra Goll is the 10 percent owner of Protara Therapeutics Inc. Other key executives at Protara Therapeutics Inc include 10 percent owner Opaleye Management Inc. , Chief Financial Officer Patrick Fabbio , and director & CEO and President Jesse Shefferman .

Protara Therapeutics Inc (TARA) Insider Trades Summary

Over the past 18 months, Alexandra Goll made no insider transaction in Protara Therapeutics Inc (TARA). Other recent insider transactions involving Protara Therapeutics Inc (TARA) include a net sale of 703,460 shares made by Opaleye Management Inc. ,

In summary, during the past 3 months, insiders sold 392,421 shares of Protara Therapeutics Inc (TARA) in total and bought 0 shares, with a net sale of 392,421 shares. During the past 18 months, 703,460 shares of Protara Therapeutics Inc (TARA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 703,460 shares.

Protara Therapeutics Inc (TARA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Protara Therapeutics Inc Insider Transactions

No Available Data

What does Enanta Pharmaceuticals Inc do?

Who are the key executives at Enanta Pharmaceuticals Inc?

Alexandra Goll is the 10 percent owner of Enanta Pharmaceuticals Inc. Other key executives at Enanta Pharmaceuticals Inc include Chief Medical Officer Scott T. Rottinghaus , Sr. VP & New Product Dev. Tara Lynn Kieffer , and Sr. VP & Business Dev. Brendan Luu .

Enanta Pharmaceuticals Inc (ENTA) Insider Trades Summary

Over the past 18 months, Alexandra Goll made no insider transaction in Enanta Pharmaceuticals Inc (ENTA). Other recent insider transactions involving Enanta Pharmaceuticals Inc (ENTA) include a net sale of 12,479 shares made by Scott T. Rottinghaus , a net sale of 9,391 shares made by Tara Lynn Kieffer , and a net sale of 15,295 shares made by Terry Vance .

In summary, during the past 3 months, insiders sold 11,945 shares of Enanta Pharmaceuticals Inc (ENTA) in total and bought 0 shares, with a net sale of 11,945 shares. During the past 18 months, 53,756 shares of Enanta Pharmaceuticals Inc (ENTA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 53,756 shares.

Enanta Pharmaceuticals Inc (ENTA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Enanta Pharmaceuticals Inc Insider Transactions

No Available Data

What does Concert Pharmaceuticals Inc do?

Who are the key executives at Concert Pharmaceuticals Inc?

Alexandra Goll is the 10 percent owner of Concert Pharmaceuticals Inc. Other key executives at Concert Pharmaceuticals Inc include Chief Development Officer James V Cassella , CFO & PFO Marc A. Becker , and Chief Operating Officer Nancy Stuart .

Concert Pharmaceuticals Inc (CNCE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Concert Pharmaceuticals Inc (CNCE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Concert Pharmaceuticals Inc (CNCE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Concert Pharmaceuticals Inc (CNCE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Concert Pharmaceuticals Inc Insider Transactions

No Available Data

What does Argos Therapeutics Inc do?

Who are the key executives at Argos Therapeutics Inc?

Alexandra Goll is the 10 percent owner of Argos Therapeutics Inc. Other key executives at Argos Therapeutics Inc include Vice President and CFO Richard D Katz , 10 percent owner Public Joint Stock Co Pharmstandard , and 10 percent owner Pharmstandard International S.a. .

Argos Therapeutics Inc (ARGSQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Argos Therapeutics Inc (ARGSQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Argos Therapeutics Inc (ARGSQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Argos Therapeutics Inc (ARGSQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Argos Therapeutics Inc Insider Transactions

No Available Data

What does bluebird bio Inc do?

Who are the key executives at bluebird bio Inc?

Alexandra Goll is the 10 percent owner of bluebird bio Inc. Other key executives at bluebird bio Inc include Chief Commercial Officer & SGD Thomas J Klima , President of SGD Andrew Obenshain , and Chief Medical Officer Richard A Colvin .

bluebird bio Inc (BLUE) Insider Trades Summary

Over the past 18 months, Alexandra Goll made no insider transaction in bluebird bio Inc (BLUE). Other recent insider transactions involving bluebird bio Inc (BLUE) include a net sale of 28,872 shares made by Andrew Obenshain , a net sale of 16,173 shares made by Thomas J Klima , and a net sale of 9,710 shares made by Richard A Colvin .

In summary, during the past 3 months, insiders sold 0 shares of bluebird bio Inc (BLUE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 64,498 shares of bluebird bio Inc (BLUE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 64,498 shares.

bluebird bio Inc (BLUE)'s detailed insider trading history can be found in Insider Trading Tracker table.

bluebird bio Inc Insider Transactions

No Available Data

Alexandra Goll Mailing Address

Above is the net worth, insider trading, and ownership report for Alexandra Goll. You might contact Alexandra Goll via mailing address: 101 Arch Street, Suite 1950, Boston Ma 02110.

Discussions on Alexandra Goll

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.